Skip to main content

Table 1 Participant demographics

From: Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin

Measure ASD (n = 13) Neurotypicals (n = 15) Test statistic
Age at visit 1 (years) 30.6 ± 11.2 [20–50] 28.5 ± 6.1 [21–40] F(1, 26) = 0.389, p = .538
ADI coma 7.5 ± 5.0   
ADI repa 4.0 ± 2.6   
ADOS com 4.4 ± 3.3   
ADOS soc 7.6 ± 4.1   
AQa 29.1 ± 13.7   
FSIQ 113.0 ± 18.1 125.3 ± 12.7 F(1, 26) = 4.421, p = .045
TV1–V2 (days) 31.2 ± 17.9 28.1 ± 15.0 F(1, 26) = 0.248, p = .623
Mean motion (CBDV) 0.015 ± 0.067 0.008 ± 0.043 F(1, 26) = 0.100, p = .754
Mean motion (PLC) 0.014 ± 0.049 0.008 ± 0.050 F(1, 26) = 0.097, p = .758
  1. Demographics (mean ± standard deviation [range])) and test statistic of between-group comparison
  2. ADI autism diagnostic interview (com, communication domain; rep, restricted and repetitive behaviours domain), ADOS autism diagnostic observation schedule (com, communication domain; soc, social domain), AQ autism quotient, CBDV cannabidivarin, FSIQ full-scale intelligence quotient, PLC placebo, TV1V2, time between visits 1 and 2
  3. an = 10